MRC1 and neoplasm: In addition, flow cytometry analysis showed that OXA-NO could promote a significant decrease in tumor M2-type CD206+ and a significant increase in anti-tumor M1-type CD11c+ by releasing NO in hypoxic tumors, with a shift in TAM from M2-type to M1-type.